AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30070885 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CH) group with snack of high content of complex carbohydrates
Number of subjects: 19
Study 30070885 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFA) group with snack of high content of MUFA
Number of subjects: 19
Study 30070885 — intervention group
Group type: COMPARATOR
Intervention: Control group with a minimum fast for three hours before the training session
Number of subjects: 19
Study 26849684 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg)
Number of subjects: 284
Study 26849684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 25403296 — intervention group
Group type: EXPERIMENTAL
Intervention: Noofen (15‐20 mg/kg, 500‐700 mg per day, perorally in 2‐3 doses)
Number of subjects: 50
Study 25403296 — intervention group
Group type: COMPARATOR
Intervention: Low doses of multivitamins (Control)
Number of subjects: 50
Study 22081557 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 552
Study 22081557 — intervention group
Group type: COMPARATOR
Intervention: Thiazolidinediones (TZDs)
Number of subjects: 552
Study 20846424 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in various antioxidant-rich foods
Number of subjects: 102
Study 20846424 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiwifruit diet (three kiwifruits/d added to the regular diet)
Number of subjects: 102
Study 20846424 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 17667984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril plus irbesartan
Number of subjects: 0
Study 17667984 — intervention group
Group type: COMPARATOR
Intervention: Ramipril plus placebo
Number of subjects: 0
Study 16194890 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment hemoglobin values
Number of subjects: 152
Study 16194890 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of complete/partial remission
Number of subjects: 152
Study 16194890 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced stage (II-IV vs. I-II)
Number of subjects: 152
Study 16194890 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment hemoglobin values
Number of subjects: 152
Study 12200889 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin plus co-amoxiclav
Number of subjects: 4826
Study 12200889 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav
Number of subjects: 4826
Study 12200889 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav plus erythromycin placebo
Number of subjects: 4826
Study 12200889 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin plus co-amoxiclav placebo
Number of subjects: 4826
Study 12200889 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav placebo plus erythromycin placebo
Number of subjects: 4826
Study 9500565 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 20
Study 9500565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9500565 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 20
Study 7608485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 0
Study 7608485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30806017 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% patch
Number of subjects: 90
Study 30806017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 30014814 — intervention group
Group type: EXPERIMENTAL
Intervention: Height-for-age z-score (HAZ)
Number of subjects: 1649
Study 30014814 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-for-age z-score (WAZ)
Number of subjects: 1649
Study 26720250 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegAsp[BIDSimple]
Number of subjects: 272
Study 26720250 — intervention group
Group type: COMPARATOR
Intervention: IDegAsp[BIDStep-wise]
Number of subjects: 272
Study 24716631 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Ageing Perceptions Questionnaire (B-APQ)
Number of subjects: 6718
Study 24716631 — intervention group
Group type: COMPARATOR
Intervention: Original 32-item Ageing Perceptions Questionnaire (APQ)
Number of subjects: 6718
Study 20467629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg taken four times a day for one week)
Number of subjects: 61
Study 20467629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 17874878 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent alcohol and tobacco treatment
Number of subjects: 0
Study 15564947 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (500 mg)
Number of subjects: 10
Study 15564947 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (800 mg)
Number of subjects: 10
Study 15564947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11571099 — intervention group
Group type: EXPERIMENTAL
Intervention: High BDI scores in women
Number of subjects: 0
Study 11571099 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased clinic visits
Number of subjects: 0
Study 11571099 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender effect on diagnosis
Number of subjects: 0
Study 11571099 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and marital status
Number of subjects: 0
Study 9456412 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof lens with PMMA haptics
Number of subjects: 90
Study 9456412 — intervention group
Group type: COMPARATOR
Intervention: PMMA lens
Number of subjects: 90
Study 9456412 — intervention group
Group type: COMPARATOR
Intervention: Silicone lens
Number of subjects: 90
Study 7946872 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 100 mg and morphine 3 mg (group 3)
Number of subjects: 31
Study 7946872 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 100 mg and morphine 1 mg (group 2)
Number of subjects: 31
Study 7946872 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 100 mg (group 1)
Number of subjects: 31
Study 2899528 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dietary counselling for 6 months
Number of subjects: 137
Study 2899528 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dietary counselling for 12 months (6 months additional follow-up)
Number of subjects: 137
Study 31999376 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously once every 6 months for 12 to 36 months
Number of subjects: 10036
Study 31999376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10036
Study 30558577 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mid-arm muscle area (MAMA)
Number of subjects: 2369
Study 30558577 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher body mass index (BMI)
Number of subjects: 2369
Study 30558577 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maternal weight
Number of subjects: 2369
Study 30558577 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mid-upper arm circumference (MUAC)
Number of subjects: 2369
Study 30558577 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher MAMA
Number of subjects: 2369
Study 30558577 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher MUAC, BMI, and maternal weight
Number of subjects: 2369
Study 28182503 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose Nasal Spray (GLUC NAS)
Number of subjects: 11
Study 28182503 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine Nasal Spray (CAF NAS)
Number of subjects: 11
Study 28182503 — intervention group
Group type: COMPARATOR
Intervention: Placebo Nasal Spray
Number of subjects: 11
Study 26142584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil dosage frequency ≤1 weekly
Number of subjects: 1699
Study 26142584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil dosage frequency 2-3 weekly
Number of subjects: 1699
Study 26142584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil dosage frequency 4-7 weekly
Number of subjects: 1699
Study 23033239 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (mean weekly dose of 88,865 IU)
Number of subjects: 109
Study 23033239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 21085591 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-CMDR (10^8 pfu IM)
Number of subjects: 48
Study 21085591 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-CMDR (10^7 pfu IM)
Number of subjects: 48
Study 21085591 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-CMDR (10^6 pfu ID)
Number of subjects: 48
Study 21085591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 17525774 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% with hyaluronidase 15 IU/ml
Number of subjects: 19
Study 17525774 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% alone (control)
Number of subjects: 19
Study 16148817 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal artery thermometer
Number of subjects: 44
Study 16148817 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary artery catheter
Number of subjects: 44
Study 16148817 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary thermometer
Number of subjects: 44
Study 12660058 — intervention group
Group type: EXPERIMENTAL
Intervention: VIT (venom immunotherapy)
Number of subjects: 68
Study 12660058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 12660058 — intervention group
Group type: COMPARATOR
Intervention: Placebo to VIT crossover
Number of subjects: 68
Study 10385577 — intervention group
Group type: EXPERIMENTAL
Intervention: Young subjects (n = 32)
Number of subjects: 52
Study 10385577 — intervention group
Group type: COMPARATOR
Intervention: Elderly subjects (n = 20)
Number of subjects: 52
Study 10385577 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 8543545 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-times-weekly, bilateral, brief pulse ECT
Number of subjects: 47
Study 8543545 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly ECT plus one simulated treatment per week
Number of subjects: 47
Study 8543545 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ECT groups
Number of subjects: 47
Study 1988388 — intervention group
Group type: EXPERIMENTAL
Intervention: One Step Skin Prep used once
Number of subjects: 120
Study 1988388 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG Prep Pad used once
Number of subjects: 120
Study 1988388 — intervention group
Group type: COMPARATOR
Intervention: ECG Prep Pad used five times
Number of subjects: 120
Study 6285450 — intervention group
Group type: EXPERIMENTAL
Intervention: pivmecillinam/pivampicillin
Number of subjects: 23
Study 6285450 — intervention group
Group type: COMPARATOR
Intervention: pivmecillinam alone
Number of subjects: 23
Study 30908587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at end tidal concentration of 1.32% ± 1.0%
Number of subjects: 0
Study 30908587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at end tidal concentration of 2% for 4 minutes before cannulation attempt
Number of subjects: 0
Study 30908587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane concentration adjusted using Dixon and Massey up and down method
Number of subjects: 0
Study 30041145 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS (2.5 mA, 15 min)
Number of subjects: 14
Study 30041145 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tsDCS (2.5 mA, 15 min)
Number of subjects: 14
Study 30041145 — intervention group
Group type: COMPARATOR
Intervention: Sham tsDCS (15 min)
Number of subjects: 14
Study 27185843 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin 1.1 mg/m² plus Doxorubicin 60 mg/m²
Number of subjects: 115
Study 27185843 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 75 mg/m²
Number of subjects: 115
Study 27185843 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin plus Doxorubicin
Number of subjects: 115
Study 27185843 — intervention group
Group type: EXPERIMENTAL
Intervention: FAS and p53 expression
Number of subjects: 115
Study 24607844 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation Therapy (SMT)
Number of subjects: 199
Study 24607844 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Therapy (high dose, supervised low-tech trunk exercise)
Number of subjects: 199
Study 24607844 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course of home exercise and self-care advice
Number of subjects: 199
Study 22417189 — intervention group
Group type: EXPERIMENTAL
Intervention: New Beginnings Program
Number of subjects: 240
Study 18091486 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie treatment
Number of subjects: 260
Study 18091486 — intervention group
Group type: COMPARATOR
Intervention: Strengthening training
Number of subjects: 260
Study 18091486 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 260
Study 15034503 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% topical minoxidil
Number of subjects: 381
Study 15034503 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% topical minoxidil
Number of subjects: 381
Study 15034503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study 11489238 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9552779 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisional morphine (5 mg)
Number of subjects: 46
Study 9552779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (5 mg)
Number of subjects: 46
Study 9552779 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine (5 mg)
Number of subjects: 46
Study 9552779 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 46
Study 9552779 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall morphine and acetaminophen consumption
Number of subjects: 46
Study 7925214 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1
Number of subjects: 26
Study 7925214 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg kg‐1
Number of subjects: 26
Study 7925214 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium 0.085 mg kg‐1
Number of subjects: 26
Study 2973531 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-derived hepatitis B virus vaccine
Number of subjects: 186
Study 2973531 — intervention group
Group type: COMPARATOR
Intervention: DNA recombinant hepatitis B virus vaccine
Number of subjects: 186
Study 791318 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular metoclopramide before effervescent aspirin
Number of subjects: 2
Study 791318 — intervention group
Group type: COMPARATOR
Intervention: Effervescent aspirin alone
Number of subjects: 2
Study 27325207 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month gender-targeted weight loss program
Number of subjects: 159
Study 26403639 — intervention group
Group type: EXPERIMENTAL
Intervention: MiStent SES
Number of subjects: 149
Study 26403639 — intervention group
Group type: COMPARATOR
Intervention: Endeavor
Number of subjects: 149
Study 24584055 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral treatment (ICBT) with systematic exposure to IBS symptoms and related situations
Number of subjects: 309
Study 24584055 — intervention group
Group type: COMPARATOR
Intervention: Internet-delivered cognitive behavioral treatment without systematic exposure (ICBT‐WE)
Number of subjects: 309
Study 21648015 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care intervention
Number of subjects: 469
Study 21648015 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 469
Study 20178877 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupressure treatments
Number of subjects: 16
Study 20178877 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupressure treatments
Number of subjects: 16
Study 19031154 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsequential presentation of time, number, and length
Number of subjects: 0
Study 19031154 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential presentation of number and length
Number of subjects: 0
Study 16477953 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 4 mg
Number of subjects: 24
Study 16477953 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine 8 mg
Number of subjects: 24
Study 16477953 — intervention group
Group type: COMPARATOR
Intervention: Tiagabine 2 mg
Number of subjects: 24
Study 16477953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12735531 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy aimed at ADL activities
Number of subjects: 309
Study 12735531 — intervention group
Group type: COMPARATOR
Intervention: Leisure therapy
Number of subjects: 309
Study 10653675 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimum ST elevation model (based on > or =1 mm ST elevation in > or = 1 inferior/lateral leads, or > or =2 mm ST elevation in > or =1 anteroseptal leads)
Number of subjects: 1190
Study 10653675 — intervention group
Group type: EXPERIMENTAL
Intervention: Different definitions of 'significant' ST elevation
Number of subjects: 1190
Study 10653675 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple QRST variables in addition to ST elevation
Number of subjects: 1190
Study 8885736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine tocolysis (111 micrograms/min)
Number of subjects: 283
Study 8885736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 8885736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine tocolysis in nulliparous patients
Number of subjects: 283
Study 8885736 — intervention group
Group type: COMPARATOR
Intervention: Placebo in nulliparous patients
Number of subjects: 283
Study 8885736 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine tocolysis in parous subjects
Number of subjects: 283
Study 8885736 — intervention group
Group type: COMPARATOR
Intervention: Placebo in parous subjects
Number of subjects: 283
Study 1906447 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium preparation (5 ml, 3 times a day for 6 days)
Number of subjects: 49
Study 1906447 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study 6408016 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (200 kcal) with T3 supplementation (150 micrograms daily)
Number of subjects: 18
Study 6408016 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet (200 kcal) without T3 supplementation (control group)
Number of subjects: 18
Study 30666783 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 30666783 — intervention group
Group type: COMPARATOR
Intervention: Atosiban
Number of subjects: 0
Study 26980547 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus usual care
Number of subjects: 233
Study 26980547 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 233
Study 25396263 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical monitoring of ART
Number of subjects: 1206
Study 25396263 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing cotrimoxazole prophylaxis
Number of subjects: 1206
Study 25396263 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricting routine CD4 monitoring to after 52 weeks following ART initiation
Number of subjects: 1206
Study 25396263 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricting routine CD4 monitoring to after 52 weeks following ART initiation for older children (12+ years)
Number of subjects: 1206
Study 25396263 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued provision of cotrimoxazole
Number of subjects: 1206
Study 25396263 — intervention group
Group type: COMPARATOR
Intervention: Routine laboratory monitoring
Number of subjects: 1206
Study 24444271 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy
Number of subjects: 60
Study 24444271 — intervention group
Group type: COMPARATOR
Intervention: Delayed laparoscopic cholecystectomy
Number of subjects: 60
Study 23171524 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-oriented treatment decision aid (PORTDA-diab) offered immediately before quarterly practice consultation.
Number of subjects: 0
Study 23171524 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group).
Number of subjects: 0
Study 20044662 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced relapse prevention training for CMHTs (12 hours of training)
Number of subjects: 96
Study 20044662 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced relapse prevention training for CMHTs
Number of subjects: 96
Study 20044662 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 96
Study 17545705 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc 10 mg twice a day
Number of subjects: 48
Study 17545705 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc 25 mg twice a day
Number of subjects: 48
Study 17545705 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicriviroc 50 mg twice a day
Number of subjects: 48
Study 17545705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16334931 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible spiral drains (Blake silicon drains, Ethicon)
Number of subjects: 28
Study 16334931 — intervention group
Group type: COMPARATOR
Intervention: Standard chest drains (Dahlausen GmbH)
Number of subjects: 28
Study 16334931 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drain types
Number of subjects: 28
Study 12069671 — intervention group
Group type: EXPERIMENTAL
Intervention: Early statin therapy (median, 2.0 days after ACS; n = 3952)
Number of subjects: 12365
Study 12069671 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy (n = 8413)
Number of subjects: 12365
Study 12069671 — intervention group
Group type: EXPERIMENTAL
Intervention: Early statin therapy
Number of subjects: 12365
Study 12069671 — intervention group
Group type: COMPARATOR
Intervention: No statin therapy
Number of subjects: 12365
Study 9859922 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae DNA detection in atherosclerotic samples
Number of subjects: 238